Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW823093 in Type 2 Diabetes Mellitus (Japan Phase IIa)
NCT00370942Phase 2Terminated
- Sponsor
- GSK
- Start
- Apr 2006
- Primary completion
- Nov 2006
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of albiglutide in type 2 diabetes mellitus (T2DM), sponsored by GSK. Started Apr 2006; status: terminated.
02
Drugs
albiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00370942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00370942.